Relationship between underlying causes of HCC and its complications.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e13123-e13123
Author(s):  
Daniel Kyung ◽  
Stuthi Perimbeti ◽  
Bolanle Adepoju ◽  
Shaun Bryan Hanson ◽  
Michael Joseph McCormack ◽  
...  

e13123 Background: Hepatocellular carcinoma (HCC) remains the 4th leading cause of cancer mortality in the US. While mortality varies by stage, the presence of certain HCC-related complications contribute to increased mortality. In this study, we assessed whether the underlying cause for HCC influenced the frequency of common complications. Methods: The National Inpatient Sample between 1999 and 2014 was analyzed using ICD-9 codes. The ICD-9 code for HCC was used to extract all admissions from the years 1999-2014 and weighted to approximate the full inpatient population of the US over the 16 year interval. The prevalence of HCC-related complications were calculated for portal vein thrombosis (PVT), erythrocytosis, peritonitis, esophageal variceal bleeding (EVB), portal hypertension (Portal HTN) and hepatic encephalopathy (HE). Bivariate analysis using Chi square test was performed to compare the percentages of each complication with underlying risk factors for HCC (HBV, HCV, NASH and alcohol). Results: Total of 131,115 admissions (weighted = 648,732) was identified to have HCC. Conclusions: Portal HTN was the most common complication associated with HCV and NASH, whereas hepatic encephalopathy was most frequently seen with alcohol and PVT with HBV, respectively. Alcohol was associated with the highest rate of HCC-complications with the exception of portal vein thrombosis. HBV was associated with the lowest frequencies of complications except for PVT, for which it was the highest. Future studies might look at whether disease modifying measures such as cessation of alcohol and eradication of active HBV, HCV would impact the natural history of HCC.[Table: see text][Table: see text]

2021 ◽  
Vol 11 (1) ◽  
pp. 101
Author(s):  
Stefania Gioia ◽  
Silvia Nardelli ◽  
Oliviero Riggio ◽  
Jessica Faccioli ◽  
Lorenzo Ridola

Hepatic encephalopathy (HE) is one of the most frequent complications of cirrhosis. Several studies and case reports have shown that cognitive impairment may also be a tangible complication of portal hypertension secondary to chronic portal vein thrombosis and to porto-sinusoidal vascular disease (PSVD). In these conditions, representing the main causes of non-cirrhotic portal hypertension (NCPH) in the Western world, both overt and minimal/covert HE occurs in a non-neglectable proportion of patients, even lower than in cirrhosis, and it is mainly sustained by the presence of large porto-systemic shunt. In these patients, the liver function is usually preserved or only mildly altered, and the development of porto-systemic shunt is either spontaneous or iatrogenically frequent; HE is an example of type-B HE. To date, in the absence of strong evidence and large cooperative studies, for the diagnosis and the management of HE in NCPH, the same approach used for HE occurring in cirrhosis is applied. The aim of this paper is to provide an overview of type B hepatic encephalopathy, focusing on its pathophysiology, diagnostic tools and management in patients affected by porto-sinusoidal vascular disease and chronic portal vein thrombosis.


2017 ◽  
Vol 8 (1) ◽  
Author(s):  
Lijesh Kumar ◽  
Cyriac Abby Philips ◽  
Prakash Zacharias ◽  
Sudarshan Patil ◽  
Philip Augustine

Large spontaneous portosystemic shunts in cirrhosis are implicated in recurrent and/or chronic persistent hepatic encephalopathy. In long standing cases, these shunts lead to portal vein thrombosis and hepatic dysfunction. Balloon-occluded retrograde transvenous obliteration (BRTO) is an endovascular technique that is usually employed for shunt closure in the patients manifesting the features of chronic hepatic encephalopathy. There are several reports documenting systemic and portal vein thrombosis as a part of the procedure. We report first time a patient in whom the difficult and partial BRTO procedure led to the extensive thrombosis of the large splenorenal shunt itself without sclerosant instillation.


2011 ◽  
Vol 5 (2) ◽  
pp. 366-371 ◽  
Author(s):  
Naotaka Hashimoto ◽  
Tomohiko Akahoshi ◽  
Tetsuya Shoji ◽  
Morimasa Tomikawa ◽  
Norifumi Tsutsumi ◽  
...  

2018 ◽  
Vol 06 (11) ◽  
pp. E1283-E1288 ◽  
Author(s):  
Haoxiong Zhou ◽  
Jieying Xuan ◽  
Xianyi Lin ◽  
Yunwei Guo

Abstract Background and study aims Esophagogastric variceal bleeding (EGVB) is common in patients with portal vein thrombosis (PVT). Hereditary deficiencies in natural anticoagulant proteins, such as protein S, might contribute to PVT. However, recurrent EGVB caused by PVT in patients with protein S deficiency is seldom reported. Herein, we present the case of a 38-year-old man with protein S deficiency complicated with PVT. The patient suffered recurrent EGVB for 7 years. He underwent splenectomy plus pericardial revascularization and sequential endoscopic therapy, including one gastric variceal obturation (GVO) procedure and two esophageal variceal ligations (EVL) to eradicate the varices. Rivaroxaban was administrated to reduce risk of thrombotic events. The patient is currently well without rebleeding after 1 year of follow-up. To our knowledge there is no consensus on management of recurrent EGVB on the basis of thrombophilia complicated with PVT. According to our practice, sequential endoscopic therapy combined with anticoagulant appears to be effective and safe.


Sign in / Sign up

Export Citation Format

Share Document